Showing results (311-320 of 679) with videos related to
Sort By:
Pageof 68
Scientific Reports|April 6, 2018
The genetic diversity within the 1.4 kb HLA-G 5' upstream regulatory region moderately impacts on cellular microenvironment responsesFabrício C Dias, Bruna C Bertol, Isabelle Poras, et al.Blood Advances|July 12, 2018
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trialsAjai Chari, A Keith Stewart, Stuart D Russell, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2018
Interim PET Analysis in First-Line Therapy of Multiple Myeloma: Prognostic Value of ΔSUVmax in the FDG-Avid Patients of the IMAJEM StudyClément Bailly, Thomas Carlier, Bastien Jamet, et al.Human Immunology|December 20, 2011
Upregulation of soluble and membrane-bound human leukocyte antigen G expression is primarily observed in the milder histopathological stages of chronic hepatitis C virus infectionJanaina Cristiana de Oliveira Crispim, Tarsia Giabardo Alves Silva, Francisco José Dutra Souto, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2016
Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell TransplantationAline Clavert, Zinaida Peric, Eolia Brissot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Prognostic significance of copy-number alterations in multiple myelomaHervé Avet-Loiseau, Cheng Li, Florence Magrangeas, et al.Oncotarget|October 17, 2018
Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignanciesPatrice Chevallier, Pierre Peterlin, Alice Garnier, et al.Hematological Oncology|June 2, 2022
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysisThierry Facon, Philippe Moreau, Thomas G Martin, et al.Blood|December 4, 2015
Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myelomaNiels W C J van de Donk, Philippe Moreau, Torben Plesner, et al.Frontiers in Immunology|November 4, 2017
Pro-inflammatory State in Monoclonal Gammopathy of Undetermined Significance and in Multiple Myeloma Is Characterized by Low Sialylation of Pathogen-Specific and Other Monoclonal ImmunoglobulinsAdrien Bosseboeuf, Sophie Allain-Maillet, Nicolas Mennesson, et al.Pageof 68